GlassScriptPhysician profile
Rachel J Leland
NPI 1508182114
$8,580.83
in general payments reported to CMS, 2019-2025
20 companies · $3,399 in 2025
The $3,399 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.65 · 2021: $15.31 · 2022: $145 · 2023: $4,595 · 2024: $414 · 2025: $3,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Consulting Fee: $2,600 · Food and Beverage: $1,763 · Travel and Lodging: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Consulting Fee | $2,600.00 |
| Food and Beverage | $1,763.24 |
| Travel and Lodging | $1,044.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,094.03 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Acessa Health INC. | $2,600.00 | 2025 | Acessa Provu System |
| Hologic Sales and Service, LLC | $819.07 | 2021-2025 | Acessa Provu System, Novasure, Fluent Fluid Management System |
| Gynesonics, INC. | $243.38 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Astellas Pharma US INC | $183.35 | 2024-2025 | Veozah |
| Mayne Pharma Commercial LLC | $117.85 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $82.34 | 2024-2025 | Myfembree |
| Abbvie INC. | $78.74 | 2022 | |
| Millicent US INC | $55.39 | 2024-2025 | Femlyv, Intrarosa |
| Exeltis, USA INC. | $54.62 | 2023-2025 | Slynd |
| Coopersurgical, INC. | $53.83 | 2020-2023 | Paragard T 380a |
| Biogen, INC. | $35.15 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $33.29 | 2023-2025 | |
| Dexcom, INC. | $24.26 | 2025 | Dexcom G6 Transmitter |
| Innovation Technologies INC | $24.20 | 2025 | Irrisept |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $19.96 | 2025 | Nexplanon |
| Shield Therapeutics INC | $19.08 | 2022 | |
| Kerecis Limited | $14.44 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Myovant Sciences INC. | $14.20 | 2022 | |
| Pfizer INC. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Leland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.